Roberto Pili, MD | Authors

Articles

HDAC/mTOR Inhibitor Combination as Treatment for Prostate Cancer

April 08, 2014

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the possibility of using a HDAC/mTOR inhibitor combination as a treatment option for patients with prostate cancer.

The Efficacy of Tasquinimod in Men with mCRPC

March 28, 2014

Roberto Pili, MD, professor of oncology, chief, genitourinary section leader, Genitourinary Program, Department of Medicine, Roswell Park Cancer Center, discusses the efficacy of tasquinimod in men with metastatic castration-resistant prostate cancer